This suggests a high penetrance and a high risk of BC for the carriers; the pathogenic mutations in genes other than BRCA1/2 do not appear to be linked to OC, since all these patients have BC, only 2 of whom developed OC as second tumor. This evidence concerns the gene BRCA1 and breast cancer.